Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs
Top Cited Papers
- 12 August 2018
- journal article
- review article
- Published by Wiley in Medicinal Research Reviews
- Vol. 39 (2), 733-748
- https://doi.org/10.1002/med.21528
Abstract
Over the past decades, a multitude of experimental drugs have been shown to delay disease progression in preclinical animal models of amyotrophic lateral sclerosis (ALS) but failed to show efficacy in human clinical trials or are still waiting for approval under Phase I–III trials. Riluzole, a glutamatergic neurotransmission inhibitor, is the only drug approved by the USA Food and Drug Administration for ALS treatment with modest benefits on survival. Recently, an antioxidant drug, edaravone, developed by Mitsubishi Tanabe Pharma was found to be effective in halting ALS progression during early stages. The newly approved drug edaravone is a force multiplier for ALS treatment. This short report provides an overview of the two drugs that have been approved for ALS treatment and highlights an update on the timeline of drug development, how clinical trials were done, the outcome of these trials, primary endpoint, mechanism of actions, dosing information, administration, side effects, and storage procedures. Moreover, we also discussed the pressing issues and challenges of ALS clinical trials and drug developments as well as future outlook.Keywords
This publication has 53 references indexed in Scilit:
- Basic Concepts in Physiologically Based Pharmacokinetic Modeling in Drug Discovery and DevelopmentCPT: Pharmacometrics & Systems Pharmacology, 2013
- Improving basic and translational science by accounting for litter-to-litter variation in animal modelsBMC Neuroscience, 2013
- Calcium, mitochondria, and the pathogenesis of ALS: the good, the bad, and the uglyFrontiers in Cellular Neuroscience, 2013
- ALS clinical trialsNeurology, 2011
- Phase II screening trial of lithium carbonate in amyotrophic lateral sclerosisNeurology, 2011
- OH Radical Scavenging Activity of Edaravone: Mechanism and KineticsThe Journal of Physical Chemistry B, 2010
- Improving Bioscience Research Reporting: The ARRIVE Guidelines for Reporting Animal ResearchPLoS Biology, 2010
- Impairment of mitochondrial calcium handling in a mtSOD1 cell culture model of motoneuron diseaseBMC Neuroscience, 2009
- Legumes, lemons and streptomycin: A short history of the clinical trialCMAJ : Canadian Medical Association Journal, 2009
- Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trialsAmyotrophic Lateral Sclerosis, 2004